Literature DB >> 26879490

Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan.

Yoshihiro Tominaga1, Takatoshi Kakuta2, Chikao Yasunaga3, Michio Nakamura4, Yoshiyuki Kadokura5, Hideki Tahara6.   

Abstract

Secondary hyperparathyroidism (SHPT) remains a serious complication in patients with chronic kidney disease, and some patients require parathyroidectomy. The Parathyroid Surgeons' Society of Japan (PSSJ) evaluated parathyroidectomy for SHPT and tertiary hyperparathyroidism (THPT) in Japan. The annual numbers of parathyroidectomies between 2004 and 2013 were evaluated using questionnaires. Since 2010, the PSSJ has registered the patients. In total, 826 patients from 42 institutions were registered. The annual number of parathyroidectomies for SHPT and THPT in Japan increased from 2004 to 2007 and then decreased markedly after 2007, with 296 operations performed in 2013. The number of women and men was almost equal (397/427). Median (interquartile range) age of these patients was 59.0 (24-87) years, the duration of hemodialysis before parathyroidectomy was 10.83 (0.0-38.7) years, and diabetic nephropathy was 87/826 (10.5%). Of these patients 59.6% were treated with cinacalcet at undergoing parathyroidectomy. In 75.3% of patients, a total parathyroidectomy with forearm autograft was performed. In 77.7% of patients, four or more parathyroid glands were removed during the initial operation. The incidences of husky voice and wound hemorrhage were 2.9% and 1.1%, respectively. The number of parathyroidectomies for SHPT in Japan decreased markedly after the introduction of cinacalcet. Based on the evaluation of registered patients, parathyroidectomies have been successfully performed at the institutions participating in the PSSJ.
© 2016 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  Cinacalcet hydrochloride; Parathyroidectomy; Secondary hyperparathyroidism; Tertiary hyperparathyroidism

Mesh:

Substances:

Year:  2016        PMID: 26879490     DOI: 10.1111/1744-9987.12352

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  15 in total

Review 1.  Management of secondary hyperparathyroidism: how and why?

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2017-01-02       Impact factor: 2.801

Review 2.  Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Authors:  Wei Ling Lau; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

3.  Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia.

Authors:  Manabu Okada; Yoshihiro Tominaga; Tetsuhiko Sato; Toshihide Tomosugi; Kenta Futamura; Takahisa Hiramitsu; Toshihiro Ichimori; Norihiko Goto; Shunji Narumi; Takaaki Kobayashi; Kazuharu Uchida; Yoshihiko Watarai
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

4.  Location Frequency of Missed Parathyroid Glands After Parathyroidectomy in Patients with Persistent or Recurrent Secondary Hyperparathyroidism.

Authors:  Manabu Okada; Yoshihiro Tominaga; Takayuki Yamamoto; Takahisa Hiramitsu; Shunji Narumi; Yoshihiko Watarai
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

5.  Unexpected remission of hyperparathyroidism caused by hemorrhage due to the use of fine-needle aspiration biopsy: two cases report.

Authors:  Joon Ho; Donggyu Kim; Ji-Eun Lee; Soonmin Choi; Hyeryeon Choi; Sunhyung Choi; Jinkyung Kim; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung
Journal:  Gland Surg       Date:  2021-06

6.  The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.

Authors:  Daisuke Takada; Tatsuo Tsukamoto; Miho Fuse; Shinpei Kada; Motoko Yanagita
Journal:  BMC Nephrol       Date:  2017-10-18       Impact factor: 2.388

Review 7.  Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.

Authors:  Keith E Eidman; James B Wetmore
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-02-05

Review 8.  Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Tadao Akizawa; Kazuaki Ikejiri; Yuichiro Kondo; Yuichi Endo; Masafumi Fukagawa
Journal:  Ther Apher Dial       Date:  2019-10-23       Impact factor: 2.195

9.  Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience.

Authors:  M T Mogl; T Skachko; E M Dobrindt; P Reinke; C Bures; J Pratschke; N Rayes
Journal:  Scand J Surg       Date:  2020-01-06       Impact factor: 2.360

10.  A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.

Authors:  Takehisa Kawata; Shin Tokunaga; Miki Murai; Nami Masuda; Waka Haruyama; Youji Shoukei; Yutaka Hisada; Tetsuya Yanagida; Hiroshi Miyazaki; Michihito Wada; Tadao Akizawa; Masafumi Fukagawa
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.